Moran Kevin Patrick 4
4 · Vanda Pharmaceuticals Inc. · Filed Dec 7, 2022
Insider Transaction Report
Form 4
Moran Kevin Patrick
SVP, CFO & Treasurer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2022-12-06−7,500→ 0 totalExercise: $3.12Exp: 2022-12-06→ Common Stock (7,500 underlying) - Exercise/Conversion
Common Stock
2022-12-06$3.12/sh+7,500$23,400→ 124,952 total - Sale
Common Stock
2022-12-06$10.61/sh−4,792$50,827→ 120,160 total
Holdings
- 635(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 6, 2022 as reflected in this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $10.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]This option fully vested and exercisable.